Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05278637 · ClinicalTrials.gov registry record · Early Phase 1
GM03 - Platelet RNA Signatures of Aspirin
A Early Phase 1 study of RNA and Aspirin, sponsored by Duke University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT05278637: Completed Early Phase 1 study of RNA and Aspirin, sponsored by Duke University.
NCT05278637 is a Early Phase 1 study of RNA and Aspirin that has completed, run by Duke University. The registered enrollment target is 135 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (155% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05278637, a Early Phase 1 study of RNA and Aspirin, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Ticagrelor
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-11-01 |
| Est. Completion | 2016-12-05 |
| Phase | Early Phase 1 |
What the finished NCT05278637 record still lists
NCT05278637 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (155% higher).
The record links to 4 conditions, with RNA appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT05278637 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05278637 about?
NCT05278637 is a clinical study titled "GM03 - Platelet RNA Signatures of Aspirin". This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.
What is the current status of trial NCT05278637?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 135 participants. The study started on 2013-11-01. Estimated completion is 2016-12-05.
What conditions does trial NCT05278637 study?
This clinical trial studies the following conditions: RNA, Aspirin, Platelet Aggregation Inhibitors, Ticagrelor.
What interventions are being tested in trial NCT05278637?
The interventions under investigation include: Aspirin (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT05278637?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05278637 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RNA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05278637's enrollment target sits among peer trials
135 128th of 2000 higher than 1,872 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI